A Phase 1, Randomized, Parallel-group, Open-label, Single-dose, Relative Bioavailability Study of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
Latest Information Update: 22 Sep 2021
At a glance
- Drugs Ozanimod (Primary) ; Ozanimod
- Indications COVID 2019 infections; Crohn's disease; Multiple sclerosis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 17 Sep 2021 Status changed from recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 10 Dec 2020 to 8 Mar 2021.
- 02 Feb 2021 Planned primary completion date changed from 25 Nov 2020 to 24 Feb 2021.